Safety assessment of ustekinumab in inflammatory bowel disease: a real-world analysis based on the FDA adverse event reporting system (FAERS).

In a separate randomized, double-blind, placebo-controlled maintenance trial involving patients with UC, the incidence of influenza was higher in the UST-treated group than in the placebo group, but the difference did not reach statistical significance [ 18 ].

also in 111,027 other papers